<DOC>
	<DOCNO>NCT00976495</DOCNO>
	<brief_summary>The purpose study evaluate effect dapagliflozin kidney function , assess glomerular filtration rate .</brief_summary>
	<brief_title>Effects Dapagliflozin Kidney Function ( Glomerular Filtration Rate ) Subjects With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Hydrochlorothiazide</mesh_term>
	<criteria>Type 2 diabetes inadequate glycemic control , define A1C ≥ 6.6 ≤ 9.5 % Stable dose metformin AND/OR sulfonylurea , least 4 week prior enrollment visit Inadequate blood pressure ( BP ) control , define systolic BP ( SBP ) ≥ 130 &lt; 165 mmHg , AND/OR diastolic BP ( DBP ) ≥ 80 &lt; 105 mmHg Cpeptide ≥ 0.8 ng/mL Estimated GFR Modification Diet Renal Disease ( MDRD ) formula &gt; 60 mL/min/1.73m² &lt; 150 mL/min/1.73m² Urine albumin : creatinine ratio ( UACR ) &lt; 300 mg/g BMI ≤ 45.0 kg/m2 Administration diuretic medication approve treatment hypertension ( exception either ACEI ARB ) , dose 12 week prior enrollment visit History adverse reaction radiocontrast dye Allergy contraindication use thiazide diuretic Aspartate Aminotransferase ( AST ) &gt; 3X Upper limit normal ( ULN ) Alanine aminotransferase ( ALT ) &gt; 3X ULN Serum Total Bilirubin &gt; 1.5X ULN Serum Creatinine ( Scr ) ≥ 1.50 mg/dL ( 133 μmol/l ) men ; SCr ≥ 1.40 mg/dL ( 124 μmol/l ) woman Currently unstable serious cardiovascular , renal , hepatic , hematological , oncologic , endocrine , psychiatric , rheumatic disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>